Purpose. To review the outcome of 12 patients who underwent debridement and injection of bioceramic for unicameral bone cyst (UBC). The resorption rate of the bioceramic was estimated by both traditional and novel methods. Methods. Records of 10 males and 2 females aged 6 to 34 years who underwent debridement and injection of bioceramic for UBC and were followed up for a mean of 41 (range, 26-57) months were reviewed. Functional outcome was assessed using the selfcompleted Musculoskeletal Tumor Society (MSTS) questionnaire. Radiological outcome was assessed using both original and modified Neer Outcome Rating System. The resorption rate of the bioceramic was estimated using both traditional and novel (ImageJ) methods. Results. The mean MSTS score was 29.7 (range, 28-30) indicating excellent functional outcome. Of the 12 patients, 9 achieved complete healing and 3 had a residual cyst of 1%, 11%, and 52%. The last
was considered a local recurrence, and the patient underwent repeat percutaneous injection of the bioceramic 1.5 years later and remained disease-free 4 years later. The mean resorption rate was 29% faster when estimated using the traditional rather than the ImageJ method (0.47 vs. 0.33 cm 3 /day, p=0.02). In the patient with recurrence, the resorption rate was faster than the average (0.68 vs. 0.33 cm 3 /day). Conclusion. A single percutaneous injection of the bioceramic for UBC achieved good functional and radiological outcome while avoiding donor-site morbidity.
the use of corticosteroids, allografts, autografts, bone substitutes, or their combination. The recurrence rate of UBC has been reported to be 11% to 77%. [3] [4] [5] [6] [7] [8] [9] [10] [11] In 56 patients who underwent curettage and injection of bioceramic for benign bone tumours, the mean Musculoskeletal Tumor Society (MSTS) functional score was 29 after a mean follow-up of 42 months. 12 Autogenous bone grafts are widely used and remain the gold standard for grafting. 12 Owing to its limited supply and donor-site morbidity, the use of bone substitutes is increasingly popular. 13, 14 Calcium sulfate (CaSO 4 ) and calcium phosphate (CaPO 4 ) are osteoconductive and biodegradable, 15, 16 and have been used to treat benign bone lesions. 15, 17 An injectable composite of CaSO 4 and CaPO 4 takes advantage of their different resorption and mechanical profiles to improve the compressive strength and intermediate resorption profile when compared with CaSO4 pellets. 12, 16 The bioceramic is composed of a matrix of surgical grade 75% CaSO 4 and 25% dicalcium phosphate dihydrate (DCPD) and β-tricalcium phosphate (β-TCP) granules, which provide a triphasic resorption profile and good biocompatibility. 16 Under simple dissolution, the CaSO 4 resorbs thereby creating a porous scaffold of CaPO 4 that provides a surface for early vascular infiltration and deposition of osteoblasts and osteoclasts. The resulting scaffold surface of DCPD and β-TCP forms interconnecting pores, which is capable of binding growth factors such as vascular endothelial growth factor and bone morphogenic proteins to help recruit osteoblasts. The remaining CaPO 4 undergoes osteoclastic resorption with the DCPD creating an intermediate profile and β-TCP as the final phase of resorption. Based on a canine model with a humeral osseous defect, the composite of CaSO 4 and CaPO 4 was clinically superior to CaSO 4 and had equivalent properties to normal bone. 16 This study reviewed the outcome of 12 patients who underwent debridement and injection of bioceramic for UBC ( Fig. 1 ). The resorption rate of the bioceramic was estimated by both traditional and novel methods.
Materials and Methods
This study was approved by the institutional review board of our hospital. Records of a consecutive series of 19 patients with a UBC treated with debridement and injection of a bioceramic-Pro-Dense (Wright Medical Technology, Arlington [TN], USA)-from 2006 to 2009 by a single surgeon were retrospectively reviewed. Of them, 5 had inadequate radiographs, one was lost to follow-up, and one had hardware obstructing the view of the entire graft. The remaining 10 males and 2 females aged 6 to 34 years were followed up for a mean of 41 (range, 26-57) months. A period of 12 months is adequate to evaluate recurrence or fracture of a UBC after treatment. 4, 14, 18, 19 A percutaneous 2-needle technique was used. A small incision was made, followed by blunt dissection of the overlying cortex. A small cortical window was opened using a high-speed bur to allow aspiration of the cyst fluid and curettage of the fibrous lining for biopsy. The diagnosis was confirmed by frozen section. A second cortical window was opened under fluoroscopic guidance. The UBC was debrided through two 4-mm cannulas and then copiously lavaged with the second cortical window as an outlet. The bioceramic was prepared by mixing the powdered graft materials with aqueous diluents. It was injected into the cavity under fluoroscopy, with the second cortical window as a vent. Postoperatively, patients with a lower-limb lesion were instructed to have protected weight-bearing using crutches for 8 weeks, and those with an upperlimb lesion were instructed to avoid lifting objects for 8 weeks. Patients were followed up weekly and then at 1, 6, 12, and 18 months.
Functional outcome was assessed using the self-completed MSTS questionnaire. 20 For lower limbs, items include emotional acceptance, walking supports (including brace, prosthesis, cane, or crutches), walking ability, and gait. For upper limbs, items include function, emotional acceptance, hand positioning, dexterity, and lifting ability. Score for each item ranges from 0 to 5; the maximum total score is 30.
Radiological outcome was assessed at the final follow-up by 2 independent assessors using both original and modified Neer Outcome Rating System. 4, 18, 21, 22 For the former, outcome was considered 'excellent' when the UBC was completely obliterated, as 'residual defect' when there was single or multiple persistent cystic residua but with good bone strength, as 'reoperation' when the UBC recurred necessitating further operative intervention. For the latter, 'persistent' and 'recurrence' were considered a failure, whereas 'partially healed' and 'healed' was considered a success so long as there was good bone strength ( Table 1) .
The resorption rate of the bioceramic was estimated using both traditional and novel (ImageJ) methods (Fig. 2) . For the former, the graft volume was estimated based on the dimension (length and width) of a rectangular prism on 2 orthogonal radiographs, 23 but this does not account for irregular shapes. For the latter, the graft volume was estimated based on the length, width, and irregular shapes calibrated with a known distance marker on 2 orthogonal radiographs using the ImageJ. 24 The resorption rates estimated by the 2 methods were compared using the paired t-test. A p value of <0.05 was considered statistically significant.
results
The mean MSTS functional score was 29.7 (range, [28] [29] [30] for all patients, 29.3 for those with a lower-limb lesion, and 29.8 for those with an upper-limb lesion ( Table 2 ). According to the Neer Outcome Rating System, the outcome was excellent in 9, residual defect in 2, and reoperation in one patient. According to the Modified Neer Outcome Rating System, the outcome was healed in 9, partially healed in 2, persistent in one, and recurrence in none. For the 3 patients with a residual cyst, the volume was 1%, 11%, and 52%. The last was a 9-year-old boy with a UBC in the proximal humerus who had a local recurrence 1.5 years later ( Fig. 3) . He underwent repeat percutaneous injection of the bioceramic and remained disease-free 4 years later. No patient had postoperative fractures or wound complications.
The mean resorption rate was 29% faster when estimated using the traditional rather than ImageJ 3 /day, p=0.02). In the patient with recurrence, the resorption rate was faster than the average (0.68 vs. 0.33 cm 3 /day).
discussion
For treatment of simple bone cysts, percutaneous injection of bone marrow or methylprednisone achieves comparable Activity Scale for Kids score and Oucher pain score. 11 The recurrence rate has been reported to be 11% to 77% after a single injection of materials (corticosteroids, allograft bone, autograft bone, bone graft substitutes, or a combination of these). [3] [4] [5] [6] [7] [8] [9] [10] [11] 25 The success rate has been reported to be 77% after autogenous grafting and 69% after homogenous grafting. 22 One study reported an overall success rate of 86.7% and 92.0% following percutaneous injection of steroid and autogenous bone marrow, respectively, but the mean number of procedures performed was 2.19 and 1.57, respectively. 5 One study reported a success rate of 84.6% after a single percutaneous injection of apatitic calcium phosphate. 18 Compared with calcium sulfate pellets, Pro-Dense results in a higher percentage of bone formation, greater ultimate compressive stress, and an elastic modulus that more closely resembles normal bone. 16 Curettage and grafting with calcium sulfate pellets results in a recurrence rate of 17% to 26% and a complication rate of 0% to 8%. [26] [27] [28] In our series, the recurrence rate was 8% and the success rate was 92% after a single percutaneous injection of bioceramic.
Graft resorption can be measured based on the percentage of opacification 29 or the length and width of a rectangular prism on 2 radiographs, 17,23,30 but these methods do not accurately account for irregular shapes. This can be overcome with use of the ImageJ that is calibrated using a known distance marker. In our series, the traditional method overestimated the resorption rate by 29%. The accuracy of the Image J method could have been validated by comparing the intra-operative amount of bioceramic injected with the estimated volume on an immediate postoperative radiograph, but this would have exposed the patient to unnecessary radiation. This study had limitations. The study was retrospective in nature, and the sample size was small, but given the rarity of UBC the sample size was consistent with other studies. Graft resorption was not measured histologically to correlate with radiographic findings. Nonetheless, a bone biopsy is impractical. In one patient evaluated with computed tomography prior to returning to high-level contact sports, the results correlated with those by radiography ( Fig. 4) .
conclusion
A single percutaneous injection of the bioceramic for UBC achieved good functional and radiological outcome while avoiding donor-site morbidity.
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